Guggenheim slashes price target on Moderna Inc. [MRNA] – find out why.

Moderna Inc. [NASDAQ: MRNA] plunged by -$5.15 during the normal trading session on Tuesday and reaching a high of $129.50 during the day while it closed the day at $125.11. The company report on May 16, 2023 at 6:00 AM that Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry.

The company’s MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


With $50 million in committed capital from Flagship, Metaphore has built a first-in-class bioplatform during the past two years.

Moderna Inc. stock has also loss -6.47% of its value over the past 7 days. However, MRNA stock has declined by -28.76% in the 3 months of the year. Over the past six months meanwhile, it has lost -26.92% and lost -30.35% year-on date.

The market cap for MRNA stock reached $47.37 billion, with 386.00 million shares outstanding and 346.94 million shares in the current float. Compared to the average trading volume of 3.56M shares, MRNA reached a trading volume of 3684603 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Moderna Inc. [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $218.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 26, 2023. While these analysts kept the previous recommendation, TD Cowen raised their target price from $150 to $180. The new note on the price target was released on March 13, 2023, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise to $200, while RBC Capital Mkts analysts kept a Outperform rating on MRNA stock. On February 24, 2023, analysts decreased their price target for MRNA shares from 111 to 93.

The Average True Range (ATR) for Moderna Inc. is set at 5.11, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.15. The Price to Book ratio for the last quarter was 2.56, with the Price to Cash per share for the same quarter was set at 23.57. Price to Free Cash Flow for MRNA in the course of the last twelve months was 77.39 with Quick ratio for the last quarter at 3.30.

MRNA stock trade performance evaluation

Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.47. With this latest performance, MRNA shares dropped by -13.10% in over the last four-week period, additionally sinking by -26.92% over the last 6 months – not to mention a drop of -9.28% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 33.80, with the RSI for the last a single of trading hit 31.01, and the three-weeks RSI is set at 36.07 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 143.62, while it was recorded at 128.78 for the last single week of trading, and 156.57 for the last 200 days.

Moderna Inc. [MRNA]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +48.49 and a Gross Margin at +69.84. Moderna Inc.’s Net Margin is presently recorded at +43.76.

Return on Total Capital for MRNA is now 52.37, given the latest momentum, and Return on Invested Capital for the company is 47.81. Return on Equity for this stock inclined to 50.27, with Return on Assets sitting at 32.82. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 6.28. Additionally, MRNA Total Debt to Total Capital is recorded at 5.90, with Total Debt to Total Assets ending up at 4.60. Long-Term Debt to Equity for the company is recorded at 5.25, with the Long-Term Debt to Total Capital now at 4.94.

Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of $2,144,103 per employee. Receivables Turnover for the company is 7.71 with a Total Asset Turnover recorded at a value of 0.75.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.50.

Moderna Inc. [MRNA]: Insider Ownership positions

There are presently around $35,530 million, or 65.90% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 46,466,171, which is approximately 3.75% of the company’s market cap and around 2.40% of the total institutional ownership; VANGUARD GROUP INC, holding 27,526,280 shares of the stock with an approximate value of $3.59 billion in MRNA stocks shares; and BLACKROCK INC., currently with $3.27 billion in MRNA stock with ownership of nearly -3.916% of the company’s market capitalization.

Positions in Moderna Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 446 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 36,180,058 shares. Additionally, 544 investors decreased positions by around 11,421,252 shares, while 186 investors held positions by with 225,161,342 shares. The mentioned changes placed institutional holdings at 272,762,652 shares, according to the latest SEC report filing. MRNA stock had 120 new institutional investments in for a total of 23,909,723 shares, while 142 institutional investors sold positions of 991,959 shares during the same period.


Please enter your comment!
Please enter your name here